Tuberculosis - National Institute of Allergy and Infectious Diseases ...
Tuberculosis (TB) is a contagious disease caused by infection with Mycobacterium tuberculosis (Mtb) bacteria.. It is spread through the air when a person with TB disease of the lungs or throat coughs, speaks or sings, and people nearby breathe in these bacteria and become infect
End TB Strategy with a goal of a 90% reduction in TB incidence by 2035. Domestically, the . U.S. government’s Global TB Strategy and the National Action Plan for Combating Multidrug-resistant TB have outlined respective paths to end the TB pandemic. The COVID-19 pandemic impacted all facets of biomedical research and healthcare activities,
World TB Day 2024 – Yes! We Can End TB!
Mar 22, 2024 · There were 602 TB-related deaths in the United States in 2021, the most recent year for which data are available. TB affects the entire world, but more than 95% of TB deaths occur in low- and middle-income countries. Drug-resistant TB accounts for about one in three of all antimicrobial resistance-related deaths globally.
World TB Day 2023 – ‘Yes! We Can End TB!’
Mar 24, 2023 · TB is a challenging disease to prevent, and multidrug-resistant (MDR) and extremely-drug resistant (XDR) strains can be difficult to treat. The most recent World Health Organization (WHO) report on TB noted that in 2021 the estimated annual new cases and deaths from TB increased for the first time in more than a decade.
Establishing Preclinical Animal Models to Study Post-TB Lung …
Dec 4, 2024 · NIAID invites research applications to better understand the pathophysiology of long-term lung damage resulting from Mycobacterium tuberculosis (Mtb) and the role of the immune response during tuberculosis treatment through Notice of Special interest (NOSI): Establishing and Utilizing Preclinical Animal Models to Study Post-TB Lung Disease …
NIH Clinical Trial of Tuberculous Meningitis Drug Regimen Begins
Dec 7, 2023 · A trial of a new drug regimen to treat tuberculous meningitis (TBM) has started enrolling adults and adolescents in several countries where tuberculosis (TB) is prevalent. The trial will include 330 participants aged 15 years and older who have or are likely to have TBM based on signs and symptoms, including people living with and without HIV. Because …
Tuberculosis Drugs and Mechanisms of Action
XDR TB occurs when a Mycobacterium tuberculosis strain is resistant to isoniazid and rifampin, two of the most powerful first-line drugs, as well as key drugs of the second line regimen—any fluoroquinolone and at least one of the three injectable drugs shown above.
Tuberculosis Research Unit at Rutgers | NIAID: National Institute of ...
Bacterial and Host Heterogeneity in TB latency, persistence and progression (U19AI162598) Project 1: Bacterial and host determinants of progression, manifestations, and consequences of TB; Project leader: Jerrold Ellner; Project 2: Immune Determinants of the Course of Mycobacterium tuberculosis infection and Disease; Project leader: Padmini Salgame
Immune Mechanisms of Protection Against Mycobacterium …
The IMPAc-TB program aims to develop a comprehensive understanding of the immune responses required to prevent initial infection with Mtb, establishment of latent infection, and transition to active TB disease. To accomplish these objectives, multidisciplinary research teams will conduct immunological analyses of tissue-specific and systemic ...
Tuberculosis Diagnosis | NIAID: National Institute of Allergy and ...
Oct 27, 2016 · NIAID supports the development of new and improved diagnostic tools for faster and more accurate diagnosis of early tuberculosis (TB) disease and Mycobacterium tuberculosis (Mtb) infection, to help optimize therapy by identifying drug-resistant strains, and to track the spread of TB in a community. The Institute also encourages researchers to ...